Vaginal cancer treatment depends primarily on the stage at diagnosis, with radiation therapy serving as the backbone for most cases and surgery playing a larger role in early-stage disease. Because this cancer is rare, affecting roughly 1 in 100,000 women, treatment strategies are often adapted from what works in cervical cancer. The five-year survival rate ranges from 76% for localized disease down to 24% when cancer has spread to distant sites, so early detection significantly shapes outcomes.
How Stage Determines the Treatment Plan
Vaginal cancer is staged using the FIGO system, which ranges from Stage I (cancer confined to the vaginal wall) through Stage IVB (cancer that has spread to distant organs). Your stage determines which combination of treatments your oncology team will recommend.
For Stage I disease, both surgery and radiation are standard options. Very thin tumors, those less than half a centimeter thick, can often be treated with radiation alone. Thicker Stage I tumors are more commonly treated with surgery first, sometimes followed by radiation. For adenocarcinoma specifically, a combined approach using surgery, lymph node sampling, and a localized form of radiation may be offered.
Stages II through IVA are treated with radiation, surgery, or a combination of radiation with chemotherapy (chemoradiation). For Stage III and IVA disease, radiation is the standard treatment. Stage IVB, where cancer has spread beyond the pelvis, is treated with radiation to manage symptoms, sometimes alongside chemotherapy. At this stage, the goal shifts from cure to controlling pain, bleeding, or other problems caused by the tumor.
What Radiation Therapy Involves
Radiation is the most widely used treatment for vaginal cancer across all stages. It typically comes in two forms that are often combined: external beam radiation, which directs high-energy beams at the pelvis from outside the body, and brachytherapy, which places a radioactive source directly inside the vagina to deliver a concentrated dose to the tumor.
External beam radiation targets the tumor along with nearby lymph nodes. Treatment is delivered in daily sessions over several weeks, with a typical course running 25 to 28 sessions. Brachytherapy follows and delivers additional radiation in a smaller number of sessions, usually spaced about a week apart. Combining both methods allows doctors to treat the primary tumor aggressively while also covering areas where cancer might have spread microscopically.
Side effects from pelvic radiation can include skin irritation, fatigue, and urinary or bowel symptoms. These tend to be more pronounced when external beam radiation is used alongside brachytherapy compared to brachytherapy alone. Long-term effects can include vaginal narrowing (stenosis), which is why dilator therapy is often recommended after treatment.
Surgical Options
Surgery is most useful for early-stage vaginal cancer, where the goal is to remove the tumor with clear margins while preserving as much normal tissue as possible. The type of surgery depends on where the cancer is, how large it is, and whether it has begun to spread.
A partial vaginectomy removes only the upper portion of the vagina. A total vaginectomy removes the entire vagina. A radical vaginectomy goes further, removing the vagina along with surrounding tissue and sometimes nearby organs. In advanced or recurrent cases, a more extensive operation called pelvic exenteration may be considered, which removes the vagina along with the bladder, rectum, or both.
For younger patients with early-stage disease, fertility-sparing surgery is sometimes possible. In one reported case, a woman with early-stage clear cell adenocarcinoma underwent a radical vaginectomy with reconstruction of the vagina and preservation of the uterus, avoiding the need for chemotherapy or radiation entirely. These approaches require very early diagnosis and careful surgical planning, but they demonstrate that preserving the ability to carry a pregnancy is not always off the table.
The Role of Chemotherapy
Chemotherapy for vaginal cancer is most often given alongside radiation rather than on its own. This combination, called chemoradiation, is standard for locally advanced disease (Stages II through IVA). The chemotherapy drugs make cancer cells more vulnerable to radiation, improving the effectiveness of treatment.
The drugs used are typically borrowed from cervical cancer protocols, since vaginal cancer is too rare for large dedicated drug trials. Cisplatin-based regimens and fluorouracil are the agents most commonly used during chemoradiation.
For Stage IVB or recurrent vaginal cancer, chemotherapy may be given on its own, but no specific drug regimen has been proven to extend survival in clinical trials. In these situations, treatment is guided by what has worked in cervical cancer, and the focus is often on slowing disease progression and managing symptoms. For precancerous changes (vaginal intraepithelial neoplasia), a topical chemotherapy cream applied directly inside the vagina is sometimes used as an alternative to surgery.
Immunotherapy: Borrowed From Cervical Cancer
Because vaginal cancer shares biological similarities with cervical cancer, immunotherapy drugs approved for cervical cancer are increasingly being considered. In January 2024, the FDA approved pembrolizumab (an immune checkpoint inhibitor) in combination with chemoradiation for advanced cervical cancer after a trial showed it reduced the risk of disease progression by 41% in patients with Stage III to IVA disease. While this approval applies specifically to cervical cancer, oncologists may use it as a basis for treating advanced vaginal cancer, particularly squamous cell carcinoma, which behaves similarly.
Immunotherapy works by helping your immune system recognize and attack cancer cells that have developed ways to hide from it. Whether immunotherapy is appropriate for a given patient often depends on specific tumor characteristics, including certain protein markers on the cancer cells.
Treating Recurrent Vaginal Cancer
When vaginal cancer comes back after initial treatment, the options depend on where it recurs and what treatments were used the first time. For cancer that returns only in the vagina or pelvis without distant spread, salvage radiation can be effective. If a patient never received pelvic radiation initially, a full course of external beam radiation combined with brachytherapy is possible. If external beam radiation was already given, brachytherapy alone may be used to avoid overlapping radiation fields and excessive tissue damage.
Concurrent chemotherapy with cisplatin or a combination of platinum and paclitaxel-based drugs is often added during salvage radiation when a patient’s health allows it. For recurrences that have spread to distant sites, chemotherapy using cervical cancer regimens is the primary option, though its ability to extend survival remains unproven in clinical trials.
Recovery and Long-Term Effects
Recovery looks different depending on the treatment. After surgery, healing time ranges from a few weeks for a partial vaginectomy to several months for more extensive procedures. Vaginal reconstruction, when performed, adds complexity but can restore both physical function and anatomy.
After pelvic radiation, one of the most common long-term concerns is vaginal stenosis, where scar tissue causes the vagina to narrow and shorten. To prevent this, guidelines from multiple countries recommend using a vaginal dilator several times per week, starting a few weeks after radiation ends and continuing for years. UK guidelines suggest three times weekly for an indefinite period, while Australian guidelines recommend starting within four weeks of completing brachytherapy and continuing for at least three years. The evidence supporting dilator therapy is largely based on clinical consensus rather than rigorous trials, but it remains a widely recommended practice.
Urinary and bowel changes can persist after radiation, ranging from mild urgency or frequency to more disruptive symptoms. These side effects tend to stabilize over time but may require ongoing management. Sexual health is also commonly affected by both surgery and radiation, and rehabilitation options including pelvic floor physical therapy can help restore function gradually.